Status of vaccine research and development of vaccines for herpes simplex virus

Vaccine

Volumn 34, Issue 26, 2016, Pages 2948-2952

  Johnston, Christine ^a,c   Gottlieb, Sami L ^d   Wald, Anna ^a,b,c  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Genital herpes; Herpes simplex virus; Vaccine

Indexed keywords

HERPES SIMPLEX VACCINE;

ARTICLE; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; LOWEST INCOME GROUP; MIDDLE INCOME COUNTRY; NONHUMAN; PRIORITY JOURNAL; SOCIAL CLASS; VACCINE PRODUCTION; ANIMAL; CLINICAL TRIAL (TOPIC); HUMAN ALPHAHERPESVIRUS 1; MEDICAL RESEARCH; TRENDS;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS;

EID: 84961173378     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.12.076     Document Type: Article

References (63)

1. Gupta R., Warren T., Wald A. Genital herpes. Lancet 2007, 370(9605):2127-2137.
2. Ryder N., Jin F., McNulty A.M., Grulich A.E., Donovan B. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006. Sex Transm Infect 2009, 85(6):416-419.
3. Morris S.R., Bauer H.M., Samuel M.C., Gallagher D., Bolan G. Neonatal herpes morbidity and mortality in California, 1995-2003. Sex Transm Dis 2008, 35(1):14-18. 10.1097/OLQ.0b013e3180f62bc7.
4. Bradley H., Markowitz L.E., Gibson T., McQuillan G.M. Seroprevalence of herpes simplex virus types 1 and 2 - United States, 1999-2010. J Infect Dis 2014, 209(3):325-333.
5. Smith J.S., Robinson N.J. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002, 186(Suppl. 1):S3-S28.
6. Mertz K.J., Trees D., Levine W.C., Lewis J.S., Litchfield B., Pettus K.S., et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998, 178(6):1795-1798.
7. Lewis D.A., Müller E., Steele L., Sternberg M., Radebe F., Lyall M., et al. Prevalence and associations of genital ulcer and urethral pathogens in men presenting with genital ulcer syndrome to primary health care clinics in South Africa. Sex Transm Dis 2012, 39(11):880-885.
8. Looker K.J., Magaret A.S., Turner K.M.E., Vickerman P., Gottlieb S.L., Newman L.M. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLOS ONE 2015, 10(1):e114989.
9. Rajagopal S., Magaret A., Mugo N., Wald A. Incidence of herpes simplex virus type 2 infections in Africa: a systematic review. Open Forum Infect Dis 2014, 1(2):ofu043.
10. Flagg E.W., Weinstock H. Incidence of neonatal herpes simplex virus infections in the United States. Pediatrics 2006, 127(1):e1-e8.
11. Freeman E.E., Weiss H.A., Glynn J.R., Cross P.L., Whitworth J.A., Hayes R.J. Herpes simplex virus 2 infection increases HIV acquisition in men and wom systematic review meta-analysis of longitudinal studies. AIDS 2006, 20(1):73-83.
12. Johnson K., Sherman M., Ssempiija V., Tobian A., Zenilman J., Duggan M., et al. Foreskin inflammation is associated with HIV and herpes simplex virus type-2 infections in Rakai, Uganda. AIDS 2009, 23(14):1807-1815.
13. Rebbapragada A., Wachihi C., Pettengell C., Sunderji S., Huibner S., Jaoko W., et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007, 21(5):589-598.
14. Gray R.H., Wawer M.J., Brookmeyer R., Sewankambo N.K., Serwadda D., Wabwire-Mangen F., et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual HIV-1-discordant couples in Rakai, Uganda. Lancet 2001, 357(9263):1149-1153.
15. Freeman E.E., Orroth K., White R., Glynn J.R., Bakker R., Boily M.C., et al. The proportion of new HIV infections attributable to HSV-2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex Transm Infect 2007.
16. Masese L., Baeten J.M., Richardson B.A., Bukusi E., John-Stewart G., Graham S.M., et al. Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. AIDS 2015, 29(9):1077-1085.
17. Owusu-Edusei K.J., Chesson H.W., Gift T.L., Tao G., Mahajan R., Ocfemia M.C.B., et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013, 40(3):197-201.
18. Vos T., Barber R.M., Bell B., Bertozzi-Villa A., Biryukov S., Bolliger I., et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study. Lancet 2013, 386(9995):743-800.
19. Lingappa J., Nakku-Joloba E., Magaret A., Friedrich D., Dragavon J., Kambugu F., et al. Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans. Int J STD AIDS 2010, 21(9):611-616.
20. Workowski K.A., Bolan G. Sexually transmitted diseases treatment guidelines, 2015. MMWR 2015, 64(RR3):1-137.
21. Burris H., Parkhurst J., Adu-Sarkodie Y., Mayaud P. Getting research into policy - herpes simplex virus type-2 (HSV-2) treatment and HIV infection: international guidelines formulation and the case of Ghana. Health Res Policy Syst 2011, 9(Suppl. 1):S5.
22. Corey L., Wald A., Patel R., Sacks S.L., Tyring S.K., Warren T., et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004, 350(1):11-20.
23. Mujugira A., Magaret A.S., Celum C., Baeten J.M., Lingappa J.R., Morrow R.A., et al. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J Infect Dis 2013, 208(9):1366-1374.
24. Celum C., Wald A., Hughes J., Sanchez J., Reid S., Delany-Moretlwe S., et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371(9630):2109-2119.
25. Celum C., Wald A., Lingappa J.R., Magaret A.S., Wang R.S., Mugo N., et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010, 362(5):427-439.
26. Martin E.T., Krantz E., Gottlieb S.L., Magaret A.S., Langenberg A., Stanberry L., et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med 2009, 169(13):1233-1240.
27. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352(22):2271-2284.
28. Lal H., Cunningham A.L., Godeaux O., Chlibek R., Diez-Domingo J., Hwang S.-J., et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015, 372(22):2087-2096.
29. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943.
30. Belshe R.B., Leone P.A., Bernstein D.I., Wald A., Levin M.J., Stapleton J.T., et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012, 366(1):34-43.
31. Belshe R.B., Heineman T.C., Bernstein D.I., Bellamy A.R., Ewell M., van der Most R., et al. Correlate of immune protection against HSV-1 genital disease in vaccinated women. J Infect Dis 2014, 209(6):828-836.
32. United States Department of Agriculture Psuedorabies (Aujeszky's disease) and its eradication: a review of the U.S. experience Animal and Plant Health Inspection Service, October 2008, Technical Bulletin No. 1923.
33. Raaperi K., Orro T., Viltrop A. Epidemiology and control of bovine herpesvirus 1 infection in Europe. Vet J 2014, 201(3):249-256.
34. Newman R.M., Lamers S.L., Weiner B., Ray S.C., Colgrove R.C., Diaz F., et al. Genome sequencing and analysis of geographically diverse clinical isolates of herpes simplex virus 2. J Virol 2015.
35. Kolb A.W., Larsen I.V., Cuellar J.A., Brandt C.R. Genomic, phylogenetic, and recombinational characterization of herpes simplex virus 2 strains. J Virol 2015, 89(12):6427-6434.
36. Szpara M.L., Gatherer D., Ochoa A., Greenbaum B., Dolan A., Bowden R.J., et al. Evolution and diversity in human herpes simplex virus genomes. J Virol 2014, 88(2):1209-1227.
37. Wald A., Bernstein D., Fife K., Lee P., Tyring S., Van Wagoner N. Novel therapeutic vaccine for genital herpes reduces genital HSV-2 shedding. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy 2013.
38. Schiffer J.T., Mayer B.T., Fong Y., Swan D.A., Wald A. Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding. J R Soc Interface 2014, 11(95).
39. Dasgupta G., BenMohamed L. Of mice and not humans: how reliable are animal models for evaluation of herpes CD8+-T cell-epitopes-based immunotherapeutic vaccine candidates?. Vaccine 2011, 29(35):5824-5836.
40. Stanberry L., Kern E., Richard J., Abbott T., Overall J. Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis 1982, 146:397-404.
41. Sandlin M.I., Johnston C., Bowe D., Saracino M., Schacker T., Shaughnessy M., et al. Clinician and patient recognition of anogenital herpes disease in HIV positive men who have sex with men. Sex Transm Dis 2011, 38(9):833-836.
42. Cairns T.M., Huang Z.-Y., Whitbeck J.C., Ponce de Leon M., Lou H., Wald A., et al. Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans. J Virol 2014, 88(21):12612-12622.
43. Plotkin S.A., Gilbert P.B. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012, 54(11):1615-1617.
44. Petro C., González P.A., Cheshenko N., Jandl T., Khajoueinejad N., Bénard A., et al. Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. eLife 2015, 4:e06054.
45. Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism?. Clin Diagn Lab Immunol 2004, 11(3):437-445.
46. Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation 2013, Available from: http://www.agenusbio.com/docs/press-releases/2013/herpv-vaccine-for-genital-herpes-meets-primary-endpoint.php [accessed 09.12.15].
47. Zhu J., Peng T., Johnston C., Phasouk K., Kask A.S., Klock A., et al. Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature 2013, 497(7450):494-497.
48. Shin H., Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 2012, 491(7424):463-467.
49. Awasthi S., Huang J., Shaw C., Friedman H.M. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance Efficacy of a trivalent subunit antigen vaccine for genital herpes. J Virol 2014, 88(15):8421-8432.
50. Freeman E.E., White R.G., Bakker R., Orroth K.K., Weiss H.A., Buve A., et al. Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine 2009, 27(6):940-946.
51. Long D., Skoberne M., Gierahn T.M., Larson S., Price J.A., Clemens V., et al. Identification of novel virus-specific antigens by CD4+ and CD8+ T cells from asymptomatic HSV-2 seropositive and seronegative donors. Virology 2014, 464-465:296-311.
52. Skoberne M., Cardin R., Lee A., Kazimirova A., Zielinski V., Garvie D., et al. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in guinea pigs. J Virol 2013, 87(7):3930-3942.
53. Wald A., Koelle D.M., Fife K., Warren T., Leclair K., Chicz R.M., et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 2011, 29(47):8520-8529.
54. Dutton J.L., Li B., Woo W.-P., Marshak J.O., Xu Y., Huang M.-l., et al. A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice. PLOS ONE 2013, 8(10):e76407.
55. ®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 2012, 30(49):7046-7051.
56. Bernard M.-C., Barban V., Pradezynski F., de Montfort A., Ryall R., Caillet C., et al. Immunogenicity protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and Guinea pigs. PLOS ONE 2015, 10(4):e0121518.
57. Halford W.P., Puschel R., Gershburg E., Wilber A., Gershburg S., Rakowski B. A live-attenuated HSV-2 ICP0-virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS ONE 2011, 6(3):e17748.
58. Luo C., Goshima F., Kamakura M., Mutoh Y., Iwata S., Kimura H., et al. Immunization with a highly attenuated replication-competent herpes simplex virus type 1 mutant HF10, protects mice from genital disease caused by herpes simplex virus type 2. Front Microbiol 2012, 3:158.
59. Prichard M.N., Kaiwar R., Jackman W.T., Quenelle D.C., Collins D.J., Kern E.R., et al. Evaluation of AD472: a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 2005, 23(46-47):5424-5431.
60. Zhang P., Xie L., Balliet J.W., Casimiro D., Yao F. Herpes simplex virus 2 (HSV-2) glycoprotein dexpressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in Guinea pigs. PLOS ONE 2014, 9(6):1-9.
61. Morello C.S., Kraynyak K.A., Levinson M.S., Chen Z., Lee K.-F., Spector D.H. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine 2012, 30(46):6541-6550.
62. Chiuppesi F., Vannucci L., De Luca A., Lai M., Matteoli B., Freer G., et al. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. J Virol 2012, 86(12):6563-6574.
63. Cortesi R., Ravani L., Rinaldi F., Marconi P., Drechsler M., Manservigi M., et al. Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes. Int J Pharm 2013, 440(2):229-237.